

Curriculum vitae: Miguel A. Alvarez

Current address:

IPLA-CSIC

Paseo Río Linares s/n

33300 Villaviciosa, Asturias

Spain

Phone: +34 985893418

E-Mail: maag@ipla.csic.es

Miguel A. Alvarez scientific training begins in 1986 as an Internal Student of the Department of Microbiology at the University of Oviedo. Between 1988 and 1991 he did his Doctoral Thesis in the same department, under the direction of Prof. Rosario Rodicio. During that period he spent several months working in the group of Prof. Keith Chater, at the John Innes Institute (Norwich, England), the international reference center in the Molecular Biology of *Streptomyces*, which at that time was his research field.

Between 1992 and 1995 he was Assistant Professor at the Institute of Biotechnology at the ETH (Zürich, Switzerland), where under the direction of Prof. James E. Bailey established a Group dedicated to develop new strategies for combinatorial biosynthesis of novel antibiotic polyketides by *Streptomyces*.

In 1995, Dr. Alvarez joined the group of Prof. Juan Evaristo Suárez at the University of Oviedo, beginning to work with lactic acid bacteria (LAB) and their bacteriophages.

In 1999 he obtained a permanent research position in the Dairy Research Institute (IPLA), which belongs to the Spanish National Research Council (CSIC), and funded the Molecular Microbiology group. As Group Leader, Dr. Alvarez continued working with LAB and phages, and started new lines of work, among which it should be noted the study of biogenic amines, since the group has become a world reference in this field.

During his career, Dr. Alvarez established fruitful relationships with numerous national and international laboratories and participated in 5 EU Projects, 16 National Projects, as well as Projects funded by important Dairy companies. Dr. Alvarez has published more than 100 articles, most of them in the first quartile (ISI), as well as numerous book chapters, divulgation articles and Congress communications. He has directed six Doctoral Theses and has 12 Patents, three of which have been licensed to private companies.